Merck Loses Nasonex Patent Case Against Apotex in N.J. Court
This article is for subscribers only.
Merck & Co.’s patent for the allergy drug Nasonex isn’t infringed by Apotex Inc., a federal judge ruled.
U.S. District Judge Peter Sheridan said today that Merck’s Schering unit had “failed to present credible evidence” of infringement, according to a court filing in Trenton, New Jersey. Sheridan also denied Apotex’s claim that Schering’s patent was invalid.